Severe asthma as the initial clinical manifestation of IgG4-related disease: a retrospective clinical study

BMC Pulmonary Medicine

Table 1 General clinical characteristics for all enrolled cases

Case	Gender	Age (y)	Onset age (y)	Eos%/n^* (%/10⁹/L)	Eos(n)^# (10⁹/L)	T-IgE^* (KU/L)	T-IgE^# (KU/L)	IgG (g/l)	IgG4^* (mg/dl)	IgG4^# (mg/dl)	Biopsic tissues	Treatment	Outcomes
1	F	57	48	18.8/1.09	0.11	1378	257	23.2	17,100	5430	Submandibular gland	GCs + TII	Refractory
2	F	56	52	40.5/3.86	0.11	2053	1311	11.52	4860	2160	Stomach + supraclavicular LN	GCs + CTX	Refractory
3	F	74	69	41.5/4.23	0.4	1626	115	12.67	1560	670	Skin + supraclavicular LN	GCs + CTX	Refractory
4	M	41	38	20.4/1.29	0.11	381	12	32.72	4020	4020	Submandibular gland	GCs + TII	Refractory
5	F	60	53	35.4/2.78	0.2	448	48	15.4	1570	780	Submandibular gland	GCs + TII	Refractory
6	F	51	46	15.6/1.45	0.3	326	186	11.5	7110	2110	Lacrimal gland	GCs + CTX	Refractory
7	M	67	63	17.1/1.53	0.3	4681	345	37.43	4890	2650	Submandibular gland	GCs + CTX	Refractory
8	M	53	43	34.3/2.1	0	2485	266	35.3	26,900	1970	Submandibular gland	GCs + CTX	Refractory
9	M	72	67	9.9/0.8	0.2	460	153	12.3	3590	2370	Submandibular gland	GCs	Cured
10	F	56	51	27.9/2.19	0.1	284	57	22.11	7490	615	Submandibular gland	GCs + CTX	Refractory
11	F	51	45	25.3/1.75	0.2	239	92	14	2080	243	Submandibular gland	GCs + CTX	Refractory
12	M	75	70	14.2/0.98	0.3	991	354	28.9	28,700	6400	Lung	GCs + CTX	Refractory

F female, M male, Eos eosinophils, Ig immunoglobulin, GC glucocorticoids, LN lymph node, TII Tripterygium wilfordii, CTX cyclophosphamide
*Before systemic glucocorticoids administration, ^#three months after the systemic glucocorticoids administration

ISSN: 1471-2466